Synageva BioPharma gives update on sebelipase alfa


Synageva BioPharma (GEVA) is out with an update on the development program for sebelipase alfa.

Enrollment is complete (and exceeded the target) in a Phase 3 trial in children and adults with LAL deficiency. Results expected in H2 2014.

Enrollment target met in Phase 2/3 trial in infants with LAL Deficiency. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs